Invitrogen™ CD63 Monoclonal Antibody (H5C6), PE, eBioscience™, Invitrogen™

Description

Description: This H5C6 monoclonal antibody reacts with human CD63, a type III member of the tetraspanin family of transmembrane proteins. CD63 is expressed intracellularly on lysosomes, endosomes, and granules of resting platelets and basophils. However, cell surface expression of CD63 can be detected on activated basophils and platelets, monocytes, macrophages, and granulocytes. This receptor is also expressed on endothelial cells, fibroblasts, and smooth muscle cells. Studies have demonstrated that CD63 associates with integrins (VLA-3 and VLA-6) and TIMP-1 to mediate the allergic response. Applications Reported: This H5C6 antibody has been reported for use in flow cytometric analysis. Applications Tested: This H5C6 antibody has been pre-titrated and tested by flow cytometric of normal human peripheral blood cells. This can be used at 5 μL (0.125 μg) per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 μm post-manufacturing filtered.

CD63, also known as LAMP-3, is a glycoprotein belonging to the tetraspanin family, primarily located in late endosomes, lysosomes, and secretory vesicles across various cell types. It is expressed intracellularly in resting platelets and basophils, but upon activation, CD63 translocates to the plasma membrane, making it a widely used marker for basophil activation. Unlike basophils, mast cells can expose CD63 without activation. CD63 is expressed on activated platelets, monocytes, macrophages, and granulocytes, as well as endothelial cells, fibroblasts, and smooth muscle cells. It interacts with integrins (such as VLA-3 and VLA-6) and TIMP-1, playing roles in mediating allergic responses, phagocytosis, and cell migration. Additionally, CD63 is involved in the regulation of H/K-ATPase trafficking and ROMK1 channels, and serves as a T-cell costimulation molecule. CD63 expression can be used to predict prognosis in early-stage carcinomas and is identical to the melanoma-associated antigen ME491 and the platelet antigen PTLGP40. Diseases associated with CD63 dysfunction include melanoma and Hermansky-Pudlak Syndrome, highlighting its significance in both immune responses and disease processes.